Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Liston

Nurse Practitioner, Family Charlotte, NC Nurse Practitioner

NPI 1225432735 CMS profile 11178087

801 E Morehead St Ste 100, Charlotte, NC 28202

Open in the dashboard

General payments

$32,819

535 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Liston of Charlotte, NC is reported in the CMS Open Payments database as having received $32,819 across 535 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,132 194
2024 General $3,621 150
2023 General $2,175 103
2022 General $7,305 68
2021 General $587 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Liston
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Laura Liston were reported at $19,132. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Laura Liston Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $587 $124 $35–$379 $132
2022 $7,305 $141 $44–$430 $149
2023 $2,175 $154 $49–$476 $160
2024 $3,621 $165 $51–$504 $164
2025 $19,132 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $15,698 88 payments
  2. Amgen Inc. $8,051 97 payments
  3. E.R. Squibb & Sons, L.L.C. $1,426 36 payments
  4. AstraZeneca Pharmaceuticals LP $1,293 44 payments
  5. Janssen Biotech, Inc. $1,039 36 payments
  6. Novartis Pharmaceuticals Corporation $764 30 payments
  7. UCB, Inc. $726 29 payments
  8. Lilly USA, LLC $592 45 payments
  9. GlaxoSmithKline, LLC. $576 18 payments
  10. Radius Health, Inc. $555 14 payments
  11. Other $2,100 98 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,450 17 payments
  2. Food and Beverage $13,594 506 payments
  3. Travel and Lodging $895 11 payments
  4. Consulting Fee $880 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $7,042 51 payments
  2. Enbrel $6,135 21 payments
  3. SKYRIZI $2,434 15 payments
  4. SAPHNELO $1,293 44 payments
  5. TREMFYA $772 28 payments
  6. EVENITY $733 27 payments
  7. Otezla $704 25 payments
  8. COSENTYX $657 25 payments
  9. BENLYSTA $576 18 payments
  10. SIMPONI ARIA $515 15 payments
  11. Other $6,483 311 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,241

Median for Nurse Practitioner: 389

Drug cost

$580,141

Median for Nurse Practitioner: $21,885

Branded share of claims

20%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 25 $194,455
Otezla Apremilast Brand 29 $143,981
Enbrel Sureclick Etanercept Brand 19 $141,583
Tymlos Abaloparatide Brand 13 $34,690
Rasuvo Methotrexate/Pf Brand 22 $16,761
Hydroxychloroquine Sulfate Generic 223 $6,961
Mycophenolate Mofetil Generic 17 $5,293
Methotrexate Methotrexate Sodium Brand 209 $4,486
Leflunomide Generic 84 $4,482
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 114 $2,945

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$44,561

Of which drugs: $2,267

Medicare patients

305

Average age 75

Services billed

2,752

239 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 49%
Depression 33%
Ischemic heart disease 27%
Chronic kidney disease 26%
Diabetes 22%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 47 337 $248
Injection, methylprednisolone acetate, 1 mg J1010 Office 24 1,200 $124

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $386
$386 — —
RINVOQ
  • AbbVie, Inc. $319
$319 25 —
TREMFYA
  • Janssen Biotech, Inc. $277
$277 — —
SKYRIZI
  • AbbVie, Inc. $240
$240 — —
TALTZ
  • Lilly USA, LLC $212
$212 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

535 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record